IL-5 priming of the PMA-induced oxidative metabolism of human eosinophils from allergic and normal subjects during a pollen season.
OBJECTIVE
To study the effect of IL-5 priming on the PMA-induced oxidative metabolism of blood eosinophils from allergic patients and healthy controls, during pollen exposure.


METHODS
Twenty birch pollen allergic patients with seasonal symptoms of rhinitis or rhinitis plus asthma were studied during the birch pollen season of Sweden. Eosinophils were purified to > 95% by Percoll gradients followed by the MACS system. Oxidative metabolism was measured by a lucigenin enhanced chemiluminescence (CL) assay. Eosinophils were primed with IL-5 and subsequently stimulated with PMA. The signal transduction mechanisms of IL-5 priming were studied using the MEK inhibitor PD 98059, the PkC inhibitors Staurosporine, Ro 318220, Gö 6983 and the PI3kinase inhibitor Wortmannin.


RESULTS
During the season, the eosinophils from the allergic patients showed a reduced t(1/2)rise compared to the non-allergic controls (P = 0.019) after stimulation. IL-5 reduced the total PMA CL response both in control and patients' cells (P = 0.012 and 0.0054 resp.), whereas it primed it in terms of the t(1/2)rise of the curves, in both groups (P = 0.012 and 0.0015 resp.). The PMA-induced CL reactions were inhibited by PD 98059, all PkC-inhibitors and Wortmannin. IL-5 priming counteracted only the MEK inhibition significantly.


CONCLUSIONS
Blood eosinophils from allergic patients are primed in vivo, as compared to eosinophils from non-allergic controls, during a pollen season. Interleukin-5 primes equally the PMA-induced oxidative metabolism of human eosinophils from healthy or allergic subjects. The mechanism of IL-5 priming after PMA stimulation of oxygen radical production is MEK independent.
Woschnagg
C
C
Asthma Research Centre, University of Uppsala, Uppsala, Sweden.
Garcia
R
R
Rak
S
S
Venge
P
P
D002352:Carrier Proteins / Q000378:metabolism / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D015848:Interleukin-5 / Q000378:metabolism* / Q000627:therapeutic use; D047908:Intracellular Signaling Peptides and Proteins; D010084:Oxidation-Reduction; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood* / Q000188:drug therapy*; D013548:Sweden; D013755:Tetradecanoylphorbol Acetate / Q000378:metabolism*
D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D015848:Interleukin-5; D047908:Intracellular Signaling Peptides and Proteins; C015482:protein kinase modulator; D013755:Tetradecanoylphorbol Acetate